Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Novo Nordisk (NVO) stock in focus as company launches its direct-to-consumer platform NovoCare Pharmacy for Wegovy delivery.

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in obesity.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas, ...

Some might argue that it's too late for investors to get in on Eli Lilly, while others could feel that its work in the diabetes and obesity markets still makes it an attractive long-term option.

Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. The removal of ...